ERBB2 and breast cancer: Intriguingly, both bufalin and Areno have been demonstrated to suppress the proliferation and survival of HER2 overexpressing breast cancer cells, along with the declination of SRC-3 (41), although the effect of Helle on the expression level of SRC-3 still remains unknown.